Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-06-08

Clinical Trial Update: Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial results evaluate omalizumab in patients with severe persistent non-atopic uncontrolled asthma. The results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2012-06-08